"We are excited to announce the approval of this important treatment and we look forward to serving patients with CAPS in
CAPS are a group of rare genetic autoinflammatory diseases causing a number of inflammatory responses such as fever, pain sensitization, bone and cartilage destruction and acute plasma protein responses. In the most severe form of CAPS, known as Neonatal-Onset Multisystem Inflammatory Disease (NOMID) or Chronic Infantile Neurological, Cutaneous, and Articular syndrome (CINCA), it is associated with increased mortality.
---
About Kineret® (anakinra)
Kineret® is an interleukin-1 receptor antagonist that in the US is indicated for reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs (DMARDs), and for the treatment of neonatal-onset multisystem inflammatory disease (NOMID, a form of cryopyrin-associated periodic syndromes (CAPS)).
In
For full US prescribing information visit www.kineretrx.com and for full European prescribing information visit the EMA website.
About CAPS
Cryopyrin associated periodic syndromes (CAPS) are a group of rare inherited autoinflammatory diseases caused by autosomal dominant mutations in a gene called NLRP3. CAPS is characterized by uncontrolled overproduction of IL-1beta. IL-1 induces a number of inflammatory responses such as fever, pain sensitization, bone and cartilage destruction and acute plasma protein responses. In the most severe form of CAPS, called Neonatal-Onset Multisystem Inflammatory Disease (NOMID) or Chronic Infantile Neurological Cutaneous and Articular syndrome (CINCA), it is associated with increased mortality and fever, rash, chronic aseptic meningitis, sensorineural hearing loss, craniofacial abnormalities, and bone lesions. When of intermediate severity, called Muckle-Wells Syndrome (MWS), the disease is typically associated with episodic, intense and enduring flares and morbidity, including progressive hearing loss and kidney failure secondary to amyloidosis (a condition where amyloid proteins are deposited in organs and/or tissues). The mildest form, called Familial Cold Autoinflammatory Syndrome (FCAS), presents with cold-induced episodes of fever, rash and malaise. The incidence of CAPS is estimated to be 1:1,000,000 worldwide.
About Sobi™
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,500 people across
For more information please contact:
Paula Treutiger, Head of Communication & Investor Relations
0733 666 599
paula.treutiger@sobi.com
0767 248 830
maria.kruse@sobi.com
Postal address SE-112 76
Phone: 46 8 697 20 00 www.sobi.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/kineret---anakinra--approved-in-russia-for-the-treatment-of-caps,c3287924
https://mb.cision.com/Main/14266/3287924/1373827.pdf
(c) 2021 Cision. All rights reserved., source